437 related articles for article (PubMed ID: 18987263)
1. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
Vaziri ND; Zhou XJ
Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
[No Abstract] [Full Text] [Related]
2. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
3. The treatment of anemia in chronic kidney disease: understandings in 2006.
Levin A
Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
[TBL] [Abstract][Full Text] [Related]
4. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
5. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
6. New limits advised for anemia drugs.
Mitka M
JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
[No Abstract] [Full Text] [Related]
7. Erythropoietin, an update, and where to in the future?
Sulková S
EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
[TBL] [Abstract][Full Text] [Related]
8. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
Singh AK
Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):420-4. PubMed ID: 20689425
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin.
Howman R; Kulkarni H
Nephrol Dial Transplant; 2007 May; 22(5):1462-4. PubMed ID: 17314208
[No Abstract] [Full Text] [Related]
10. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
11. Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
Parfrey PS
Am J Nephrol; 2010; 31(6):565-6. PubMed ID: 20501992
[No Abstract] [Full Text] [Related]
12. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con.
Himmelfarb J; Szczech LA
J Am Soc Nephrol; 2009 Jul; 20(7):1441-3. PubMed ID: 19579287
[No Abstract] [Full Text] [Related]
13. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
Singh AK
Am J Nephrol; 2010; 31(6):552-6; discussion 563-4. PubMed ID: 20501988
[No Abstract] [Full Text] [Related]
14. Erythropoiesis-stimulating agents--time for a reevaluation.
Unger EF; Thompson AM; Blank MJ; Temple R
N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
[No Abstract] [Full Text] [Related]
15. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
16. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
Gupta G; Choi MJ
Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
[No Abstract] [Full Text] [Related]
17. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
Krapf R; Hulter HN
Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
[TBL] [Abstract][Full Text] [Related]
18. The KDIGO anemia guideline: can reason triumph over regulation?
Wish JB
Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853
[No Abstract] [Full Text] [Related]
19. TREAT versus treatment: a patient's view of a scientific interpretation.
Prisant A
Am J Kidney Dis; 2010 Mar; 55(3):A31-2. PubMed ID: 20189046
[No Abstract] [Full Text] [Related]
20. ESAs in dialysis patients: are you a hedgehog or a fox?
Singh AK
J Am Soc Nephrol; 2010 Apr; 21(4):543-6. PubMed ID: 20357173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
